Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis
暂无分享,去创建一个
[1] Jérôme Kluza,et al. Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. , 2006, Cancer research.
[2] H. Yamaguchi,et al. Arsenic trioxide (As2O3) induces apoptosis through activation of Bax in hematopoietic cells , 2005, Oncogene.
[3] R. Rotem,et al. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. , 2005, Cancer research.
[4] C. Frezza,et al. 4-hydroxymethyl-1,6,8-trimethylfuro[2,3-h]quinolin-2(1H)-one induces mitochondrial dysfunction and apoptosis upon its intracellular oxidation. , 2005, Journal of medicinal chemistry.
[5] Shaomeng Wang,et al. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. , 2005, Molecular cancer therapeutics.
[6] G. Babcock,et al. Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization , 2004, International journal of cancer.
[7] R. D. De Abreu,et al. Bcl-2 prevents loss of mitochondria in CCCP-induced apoptosis. , 2004, Experimental cell research.
[8] G. Kroemer,et al. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA , 2004, Oncogene.
[9] R. Perez,et al. The effects of ethidium bromide induced loss of mitochondrial DNA on mitochondrial phenotype and ultrastructure in a human leukemia T-cell line (MOLT-4 cells). , 2004, Toxicology and applied pharmacology.
[10] G. Smoorenburg,et al. Ultrastructural changes in the albino guinea pig cochlea at different survival times following cessation of 8-day cisplatin administration , 2004, Acta oto-laryngologica.
[11] I. Chang,et al. Resistance of Mitochondrial DNA-depleted Cells against Cell Death , 2004, Journal of Biological Chemistry.
[12] V. De Pinto,et al. VDAC1 Is a Transplasma Membrane NADH-Ferricyanide Reductase* , 2004, Journal of Biological Chemistry.
[13] Taesoo Kim,et al. Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. , 2003, Biochemical pharmacology.
[14] N. Davies,et al. Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase -2. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[15] H. Itoh,et al. P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. , 2003, Cancer research.
[16] S. Y. Cajal,et al. Role of the p38 MAPK pathway in cisplatin-based therapy , 2003, Oncogene.
[17] S. Silbernagl,et al. Inhibition of mitochondria prevents cell death in kidney epithelial cells by intra- and extracellular acidification. , 2003, Kidney international.
[18] Johan Hansson,et al. Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling* , 2003, The Journal of Biological Chemistry.
[19] J. Perez,et al. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. , 2003, Current medicinal chemistry.
[20] C. Rudin,et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. , 2003, Cancer research.
[21] P. Devarajan,et al. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways , 2002, Hearing Research.
[22] J. Schellens,et al. DNA-based drug interactions of cisplatin. , 2002, Cancer treatment reviews.
[23] G. Amuthan,et al. Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells , 2002, Oncogene.
[24] David Polsky,et al. Focus on melanoma. , 2002, Cancer cell.
[25] H. You,et al. Rac1 prevents cisplatin‐induced apoptosis through down‐regulation of p38 activation in NIH3T3 cells , 2002, FEBS letters.
[26] P. Devarajan,et al. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. , 2002, Journal of the American Society of Nephrology : JASN.
[27] S. Isonishi,et al. Mitochondria in platinum resistant cells. , 2001, Human cell.
[28] G. Singh,et al. Mitochondrial contributions to cancer cell physiology: potential for drug development. , 2001, Advanced drug delivery reviews.
[29] J. Essigmann,et al. Mechanisms of resistance to cisplatin. , 2001, Mutation research.
[30] José Perez,et al. Is cisplatin-induced cell death always produced by apoptosis? , 2001, Molecular pharmacology.
[31] Christian Renken,et al. Preservation of Mitochondrial Structure and Function after Bid- or Bax-Mediated Cytochrome c Release , 2000, The Journal of cell biology.
[32] G. Kroemer,et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis , 2000, Oncogene.
[33] B. Joseph,et al. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. , 1999, Cancer research.
[34] Dean P. Jones,et al. Cytochrome c-mediated Apoptosis in Cells Lacking Mitochondrial DNA , 1999, The Journal of Biological Chemistry.
[35] D. Green,et al. Caspases Induce Cytochrome c Release from Mitochondria by Activating Cytosolic Factors* , 1999, The Journal of Biological Chemistry.
[36] B. Liang,et al. Increased sensitivity to cis-diamminedichloroplatinum induced apoptosis with mitochondrial DNA depletion , 1998, Cell Death and Differentiation.
[37] M. Anderson,et al. Glutathione: an overview of biosynthesis and modulation. , 1998, Chemico-biological interactions.
[38] N. Kaplowitz,et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol‐treated rats: Effect of membrane physical properties and S‐adenosyl‐L‐methionine , 1997, Hepatology.
[39] N. Kaplowitz,et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. , 1997, The American journal of physiology.
[40] Guy S. Salvesen,et al. X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.
[41] J. Fagerberg,et al. Pharmacokinetics of cisplatin and its monohydrated complex in humans. , 1996, Journal of pharmaceutical sciences.
[42] N. Kaplowitz,et al. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. , 1995, Molecular pharmacology.
[43] M. Poirier,et al. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. , 1995, Mutation research.
[44] M. Raff,et al. Programmed cell death and Bcl‐2 protection in the absence of a nucleus. , 1994, The EMBO journal.
[45] John Calvin Reed,et al. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA , 1993, Nature.
[46] P. Andrews,et al. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. , 1992, Cancer research.
[47] P. Andrews,et al. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. , 1992, Cancer research.
[48] A. Meister,et al. Inhibition of glutathione synthesis in the newborn rat: a model for endogenously produced oxidative stress. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[49] A. Pa,et al. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990 .
[50] M. King,et al. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. , 1989, Science.
[51] K. Tamura,et al. Rapid isolation method of animal mitochondrial DNA by the alkaline lysis procedure , 1988, Biochemical Genetics.
[52] C. Sorenson,et al. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. , 1988, Cancer research.
[53] A. Meister,et al. Origin and turnover of mitochondrial glutathione. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[54] F. Tietze. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. , 1969, Analytical biochemistry.
[55] G. Singh,et al. Evidence for lack of mitochondrial DNA repair followingcis-dichlorodiammineplatinum treatment , 2008, Cancer Chemotherapy and Pharmacology.
[56] H. Mouridsen,et al. Discussion at the Satellite symposium: Ifosfamide in gynecological tumors , 2004, Cancer Chemotherapy and Pharmacology.
[57] K. Tew,et al. Cellular thiols and reactive oxygen species in drug-induced apoptosis. , 2001, The Journal of pharmacology and experimental therapeutics.
[58] P. Andrews,et al. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines , 2000, Cancer Chemotherapy and Pharmacology.
[59] M. King,et al. Isolation of human cell lines lacking mitochondrial DNA. , 1996, Methods in enzymology.
[60] A. Eastman,et al. The origins of DNA breaks: a consequence of DNA damage, DNA repair, or apoptosis? , 1992, Cancer investigation.
[61] H. Bier. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo. , 1991, Acta oto-laryngologica.
[62] T. Murata,et al. Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. , 1990, Biochemistry international.
[63] S. Howell,et al. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990, Cancer cells.
[64] A. Eastman. Activation of programmed cell death by anticancer agents: cisplatin as a model system. , 1990, Cancer cells.
[65] A. Meister,et al. Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[66] S. Howell,et al. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. , 1988, Chemico-biological interactions.
[67] J. Kovach,et al. Pharmacokinetics of anticancer agents in humans , 1983 .
[68] A. Prestayko. 21 – CLINICAL PHARMACOLOGY OF CISPLATIN , 1981 .